“We are exploring all options to quickly make this important medicine available for Indian patients,” GSK India spokesperson told ET. Earlier in the day, Indian drug maker Zydus Cadila said it has sought approval from the Drug Controller of India to start clinical trials of its own antibody cocktail drug to treat mild Covid-19 patients.
